Last reviewed · How we verify

Monotherapy of medium dose ICS

Ajou University School of Medicine · FDA-approved active Small molecule

Medium-dose inhaled corticosteroid (ICS) monotherapy reduces airway inflammation by suppressing local immune responses and decreasing inflammatory mediator production in the lungs.

Medium-dose inhaled corticosteroid (ICS) monotherapy reduces airway inflammation by suppressing immune cell activation and inflammatory mediator production in the lungs. Used for Persistent asthma maintenance therapy (mild-to-moderate persistent asthma).

At a glance

Generic nameMonotherapy of medium dose ICS
SponsorAjou University School of Medicine
Drug classInhaled corticosteroid (ICS)
TargetGlucocorticoid receptor
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhaseFDA-approved

Mechanism of action

ICS agents bind to glucocorticoid receptors in airway epithelial and immune cells, suppressing the transcription of pro-inflammatory cytokines, chemokines, and adhesion molecules. This reduces eosinophil recruitment, mucus production, and airway hyperresponsiveness. Medium-dose ICS monotherapy is used as maintenance therapy to control persistent asthma symptoms and prevent exacerbations.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: